Chest · 2026
Predicting Clinical Response to Benralizumab Using CT Imaging: Prognostic CT Air-Trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients (BenraliScan) Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bourdin Arnaud, Beclin Marie Felicia, Chanez Pascal, Vachier Isabelle, Pahus Laurie, Nogue Erika, Skinner Sarah, Galeazzi David, Boulhais Myriam, Lahmar Zakaria, Volpato Mathilde, Pissarra Joana, Lafaye de Micheaux Pierre, Bommart Sebastien, Molinari Nicolas
Аннотация
BACKGROUND: Benralizumab reduces eosinophilia and improves outcomes in most, but not all, patients with asthma. We evaluated whether baseline CT imaging-derived metrics assist in clinical response prognosis after 52 weeks.
RESEARCH QUESTION: Are CT imaging-derived measures prognostic of benralizumab response, assessed by exacerbation reduction, lung function, and symptom control at 52 weeks?
STUDY DESIGN AND METHODS: This 2-center prospective, open-label study included patients eligible for anti-IL-5α receptor therapy who began benralizumab treatment alongside high-dose background therapy for severe eosinophilic asthma (SEA; > 300/mm3). Baseline variables included CT imaging-derived metrics (parametric response mapping [PRM] small airways disease [SAD] voxels; University of California, San Francisco, mucus plugging; and Lund-Mackay sinus score) and other potential biomarkers (blood eosinophil levels and lung function). The primary outcome was ≥ 50% reduction in exacerbation rates. The secondary outcome was a composite clinical score achieving ≥ 2 of response criteria: ≥ 50% exacerbation reduction, FEV1 increase of > 300 mL, and 5-item Asthma Control Questionnaire score improvement of > 0.5.
RESULTS: Of 59 enrolled patients, 47 patients (60% female; median age, 54 years) completed the study with high-quality paired inspiratory and expiratory spirometrically gated CT scans. Forty-two of 47 patients achieved ≥ 50% exacerbation reduction, for which no prognostic factor could be identified. Thirty-five of 47 patients achieved the secondary outcome. Receiver operating characteristic curve analyses indicated that PRM SAD voxels (area under the receiver operating characteristic curve [AUC], 0.693; 95% CI, 0.513-0.873) and sinus score (AUC, 0.714; 95% CI, 0.501-0.928) were robust prognostic factors of responder status, both outperforming blood eosinophil count (AUC, 0.630; 95% CI, 0.428-0.832).
INTERPRETATION: Our results show that the CT imaging-derived metrics, PRM SAD voxels, and sinus score were associated with benralizumab response as defined by a composite clinical end point and could be valuable biomarkers for response prognosis in patients with SEA. The high rate of exacerbation reduction limited discrimination of the primary end point. These findings support incorporating CT imaging phenotyping into precision management of SEA and warrant validation in larger cohorts.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03976310; URL: www.
CLINICALTRIALS: gov.
RESEARCH QUESTION: Are CT imaging-derived measures prognostic of benralizumab response, assessed by exacerbation reduction, lung function, and symptom control at 52 weeks?
STUDY DESIGN AND METHODS: This 2-center prospective, open-label study included patients eligible for anti-IL-5α receptor therapy who began benralizumab treatment alongside high-dose background therapy for severe eosinophilic asthma (SEA; > 300/mm3). Baseline variables included CT imaging-derived metrics (parametric response mapping [PRM] small airways disease [SAD] voxels; University of California, San Francisco, mucus plugging; and Lund-Mackay sinus score) and other potential biomarkers (blood eosinophil levels and lung function). The primary outcome was ≥ 50% reduction in exacerbation rates. The secondary outcome was a composite clinical score achieving ≥ 2 of response criteria: ≥ 50% exacerbation reduction, FEV1 increase of > 300 mL, and 5-item Asthma Control Questionnaire score improvement of > 0.5.
RESULTS: Of 59 enrolled patients, 47 patients (60% female; median age, 54 years) completed the study with high-quality paired inspiratory and expiratory spirometrically gated CT scans. Forty-two of 47 patients achieved ≥ 50% exacerbation reduction, for which no prognostic factor could be identified. Thirty-five of 47 patients achieved the secondary outcome. Receiver operating characteristic curve analyses indicated that PRM SAD voxels (area under the receiver operating characteristic curve [AUC], 0.693; 95% CI, 0.513-0.873) and sinus score (AUC, 0.714; 95% CI, 0.501-0.928) were robust prognostic factors of responder status, both outperforming blood eosinophil count (AUC, 0.630; 95% CI, 0.428-0.832).
INTERPRETATION: Our results show that the CT imaging-derived metrics, PRM SAD voxels, and sinus score were associated with benralizumab response as defined by a composite clinical end point and could be valuable biomarkers for response prognosis in patients with SEA. The high rate of exacerbation reduction limited discrimination of the primary end point. These findings support incorporating CT imaging phenotyping into precision management of SEA and warrant validation in larger cohorts.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03976310; URL: www.
CLINICALTRIALS: gov.